中国实用妇科与产科杂志

中国实用妇科与产科杂志 ›› 2022, Vol. 38 ›› Issue (5): 503-507.DOI: 10.19538/j.fk2022050107

• 专题笔谈 • 上一篇    下一篇

铂耐药复发卵巢上皮性癌的治疗

  

  1. 中国医学科学院北京协和医学院肿瘤医院 国家癌症中心 国家肿瘤临床医学研究中心，北京 100021
  • 出版日期:2022-05-02 发布日期:2022-05-02
  • 通讯作者: 吴令英
  • 基金资助:
    国家重点研发计划重大慢性非传染性疾病防控研究（2016YFC1303700）

Treatment for recurrent platinum-resistant epithelial ovarian carcinoma.

  1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021，China
  • Online:2022-05-02 Published:2022-05-02

摘要： 卵巢上皮性癌病死率高居妇科常见恶性肿瘤首位，铂耐药复发是棘手的临床问题。铂耐药复发卵巢癌患者非铂单药化疗有效率仅10%～20%。化疗联合抗血管药物、PARP抑制剂、免疫检查点抑制剂等在铂耐药复发卵巢癌领域开展了诸多研究，给我们带来了新的选择。但是仍存在总体有效率不高、缺乏预测疗效的有效标志物等问题。

关键词: 卵巢上皮性癌, 复发, 铂耐药, 治疗

Abstract: The case fatality rate of epithelial ovarian cancer is the highest among gynecological malignancies. Platinum resistance is a key clinical problem difficult to deal with. The efficacy of non-platinum chemotherapy is only 10%-20%. There have been many clinical trials about chemotherapy combined with anti-vascular agents，PARP inhibitors or immune checkpoint inhibitors in platinum-resistant recurrent ovarian cancer, which have brought us new choices. However, there are still some problems，such as the low overall response rate and the lack of effective markers for efficacy prediction.

Key words: epithelial ovarian cancer, recurrence, platinum resistance, treatment

中图分类号: